1-4 of 4
Hoi Kei Lon
Close
Sort by
Journal Articles

Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

Mohamed Elmeliegy, Hoi Kei Lon, Diane Wang, Wei An Ma, Lindsay King, Andrea Viqueira, Akos Czibere
Journal: Blood
Blood (2023) 142 (Supplement 1): 3345.
https://doi.org/10.1182/blood-2023-190341
Published: 2023
Journal Articles

Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies

Hoi Kei Lon, Jennifer Hibma, Jason Williams, Diane Wang, David Gifondorwa, Wei An Ma, Lindsay King, Umberto Conte, Akos Czibere, Mohamed Elmeliegy
Journal: Blood
Blood (2023) 142 (Supplement 1): 1995.
https://doi.org/10.1182/blood-2023-190102
Published: 2023
Journal Articles

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Sheena Sharma, Diane Wang, Hoi-Kei Lon, Pooneh Soltantabar, Andrea Viqueira, Akos Czibere, Anne Hickman, Jane Liang White, Mohamed Elmeliegy
Journal: Blood
Blood (2022) 140 (Supplement 1): 10036–10038.
https://doi.org/10.1182/blood-2022-169836
Published: 2022
Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere
Journal: Blood
Blood (2022) 140 (Supplement 1): 7174–7175.
https://doi.org/10.1182/blood-2022-169971
Published: 2022